Literature DB >> 6573318

Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal Caucasian volunteers.

R A Yates, I D Cockshott, H L Houghton, A Wardleworth, H Adam, R J Donnelly.   

Abstract

Cefotetan, a third-generation cephalosporin, is extremely well tolerated by healthy Caucasian volunteers when given by intramuscular injection. It gives rise to prolonged high plasma antibiotic concentrations. Lignocaine (0.5%), when used as a diluent, had no effect on the pharmacokinetic parameters of cefotetan. Two grams of cefotetan given as the disodium salt 12 hourly by the intramuscular route gives plasma levels that are likely to be clinically effective in the treatment of infections due to a very wide range of Gram-positive and Gram-negative aerobes and anaerobes. The validity of this prediction however can only be established by subsequent clinical trials.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573318     DOI: 10.1093/jac/11.suppl_a.207

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Intraperitoneal penetration of cefotetan.

Authors:  R Wise; I A Donovan; J Drumm; J Dent; S A Bennett
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

2.  Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method.

Authors:  A L Barry; R R Packer
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

Review 3.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

4.  Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

Authors:  B R Smith; J L LeFrock; P T Thyrum; B A Doret; C Yeh; G Onesti; A Schwartz; J J Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of cefotetan.

Authors:  C Martin; L Thomachot; J Albanese
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

6.  Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.

Authors:  H C Korting; M Schäfer-Korting; L Maass; N Klesel; E Mutschler
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.